Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The study comparing the incidence of cardiovascular events between high-dose ARB [angiotensin II receptor antagonists] monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk.

Next Previous
X
Search
Trial Profile

The study comparing the incidence of cardiovascular events between high-dose ARB [angiotensin II receptor antagonists] monotherapy and combination therapy with ARB and calcium channel blocker in Japanese elderly hypertensive patients at high cardiovascular risk.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olmesartan medoxomil (Primary) ; Amlodipine; Azelnidipine; Calcium channel antagonists
  • Indications Cardiovascular disorders; Hypertension
  • Focus Therapeutic Use
  • Acronyms OSCAR

    • Most Recent Events

    • 05 Apr 2011 Results presented as a late-breaking abstract at the 60th Annual Scientific Session of the American College of Cardiology.
    • 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jul 2007 Status changed from recruiting to in progress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top